Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 4 May 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 5MB, 226 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 7 results:
Author Title [ Type(Desc)] Year
Filters: Author is Clemens, A.  [Clear All Filters]
Journal Article
K. Kostikas, Price, D., Gutzwiller, F. S., Jones, B., Loefroth, E., Clemens, A., Fogel, R., Jones, R., and Cao, H., “Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database”, Int J Chron Obstruct Pulmon Dis, vol. 15, pp. 1729-1738, 2020.
D. Stolz, Kostikas, K., Loefroth, E., Fogel, R., Gutzwiller, F. S., Conti, V., Cao, H., and Clemens, A., “Differences in COPD exacerbation risk between women and men: analysis from the UK Clinical Practice Research Datalink data”, Chest, 2019.
D. Stolz, Kostikas, K., Loefroth, E., Fogel, R., Clemens, A., Gutzwiller, F. S., Conti, V., and Cao, H., “Gender differences in COPD exacerbations: Analysis from the CPRD database”, Thorax, vol. 72, p. A186, 2017.
A. M. Gallagher, van Staa, T. P., Murray-Thomas, T., Schoof, N., Clemens, A., Ackermann, D., and Bartels, D. B., “Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes”, BMJ Open, vol. 4, p. e003839, 2014.
A. M. Gallagher, de Vries, F., Plumb, J. M., Hass, B., Clemens, A., and van Staa, T. P., “Quality of INR control and outcomes following venous thromboembolism”, Clin Appl Thromb Hemost, vol. 18, pp. 370-8, 2012.
S. Lee, Monz, B. U., Clemens, A., Brueckmann, M., and Lip, G. Y., “Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database”, BMJ Open, vol. 2, 2012.
A. M. Gallagher, Setakis, E., Plumb, J. M., Clemens, A., and van Staa, T. P., “Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients”, Thromb Haemost, vol. 106, pp. 968-77, 2011.
[Page last reviewed 4 May 2021]